---
schema_version: "secwatch.filing_event.v1"
accession: "0001628908-24-000112"
form_type: "8-K"
ticker: "EVH"
cik: "0001628908"
company_name: "Evolent Health, Inc."
filed_at: "2024-11-07T23:59:59+00:00"
generated_at: "2026-05-30T03:35:56.560586+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Evolent Q3 revenue rises 21.6% to $621M, net loss $31.2M; EBITDA miss due to $42M medical cost spike

## Summary
- Revenue $621.4M, up 21.6% YoY; net loss $(31.2)M vs $(33.2)M prior year.
- Adjusted EBITDA $31.8M (5.1% margin), down from $48.7M (9.5%) YoY.
- Medical costs exceeded expectations by $42M: $24M prior-period claims, $18M oncology spike.
- Company revises 2024 Adjusted EBITDA guidance; reiterates long-term growth targets.
- Record six new contracts signed, including oncology Performance Suite with top-5 payer (200k members).

## SEC filing metadata
- accession: 0001628908-24-000112
- form_type: 8-K
- ticker: EVH
- cik: 0001628908
- company_name: Evolent Health, Inc.
- filed_at: 2024-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1628908/000162890824000112/0001628908-24-000112-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1628908/000162890824000112/evh-20241107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628908-24-000112
- JSON: https://secwatch.observer/filing/0001628908-24-000112.json
- Plain text: https://secwatch.observer/filing/0001628908-24-000112.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.